Benitec Biopharma Inc
BNTC11.500USD
+0.540+4.93%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
293.78MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Benitec Biopharma Inc Unternehmen
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Unternehmensinformationen
BörsenkürzelBNTC
Name des UnternehmensBenitec Biopharma Inc
IPO-datumJul 11, 2012
CEODr. Jerel A. Banks, M.D., Ph.D.
Anzahl der mitarbeiter16
WertpapierartOrdinary Share
GeschäftsjahresendeJul 11
Addresse3940 Trust Way
StadtHAYWARD
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl94545
Telefon15107800819
Websitehttps://benitec.com/
BörsenkürzelBNTC
IPO-datumJul 11, 2012
CEODr. Jerel A. Banks, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Managing Director
Managing Director
--
--
Dr. Jerel A. Banks, M.D., Ph.D.
Dr. Jerel A. Banks, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Edward F. Smith
Mr. Edward F. Smith
Independent Director
Independent Director
--
--
Mr. J. Kevin Buchi, CPA
Mr. J. Kevin Buchi, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Managing Director
Managing Director
--
--
Dr. Jerel A. Banks, M.D., Ph.D.
Dr. Jerel A. Banks, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2023
FY2022
FY2021
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Licensing revenue
75.00K
0.00%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Licensing revenue
75.00K
0.00%
Aktionärsstatistik
Aktualisiert: Fri, May 23
Aktualisiert: Fri, May 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Suvretta Capital Management, LLC
37.62%
Janus Henderson Investors
11.12%
Franklin Advisers, Inc.
10.90%
Adage Capital Management, L.P.
7.51%
HBM Partners AG
3.97%
Other
28.88%
Aktionäre
Aktionäre
Anteil
Suvretta Capital Management, LLC
37.62%
Janus Henderson Investors
11.12%
Franklin Advisers, Inc.
10.90%
Adage Capital Management, L.P.
7.51%
HBM Partners AG
3.97%
Other
28.88%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
51.24%
Investment Advisor/Hedge Fund
24.03%
Investment Advisor
9.80%
Corporation
2.84%
Research Firm
0.33%
Individual Investor
0.27%
Other
11.48%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
68
23.23M
88.49%
+3.01M
2025Q1
66
23.17M
88.28%
+2.93M
2024Q4
60
20.95M
89.36%
+4.31M
2024Q3
56
15.45M
85.62%
+7.92M
2024Q2
55
8.11M
85.06%
+2.49M
2024Q1
53
1.49M
56.66%
-268.80K
2023Q4
54
1.42M
56.57%
-342.85K
2023Q3
57
1.50M
61.34%
-154.56K
2023Q2
56
827.91K
52.26%
-194.13K
2023Q1
56
861.88K
54.33%
-200.92K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Suvretta Capital Management, LLC
9.88M
37.62%
+916.50K
+10.23%
Mar 31, 2025
Janus Henderson Investors
2.92M
11.12%
+302.52K
+11.56%
Mar 31, 2025
Franklin Advisers, Inc.
2.86M
10.9%
-78.56K
-2.67%
Mar 31, 2025
Adage Capital Management, L.P.
1.97M
7.51%
--
--
Mar 31, 2025
HBM Partners AG
1.04M
3.97%
+200.27K
+23.80%
Dec 31, 2024
Nantahala Capital Management, LLC
838.10K
3.19%
--
--
Mar 31, 2025
Nemean Asset Management, LLC
746.32K
2.84%
+648.12K
+659.98%
Apr 22, 2024
INFINITUM ASSET MANAGEMENT, LLC
475.00K
1.81%
+265.00K
+126.19%
Mar 31, 2025
The Vanguard Group, Inc.
327.03K
1.25%
+27.01K
+9.00%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
261.76K
1%
+1.35K
+0.52%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Simplify Health Care ETF
0.62%
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
iShares Russell 2000 ETF
0%
Simplify Health Care ETF
Anteil0.62%
iShares Micro-Cap ETF
Anteil0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.02%
iShares Russell 2000 Growth ETF
Anteil0.01%
Global X Russell 2000 ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Datum
Art
Verhältnis
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
